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Abstract
Background: The human papillomavirus (HPV) life cycle is closely linked to keratinocyte differentiation. Oncogenic
HPV infection has been shown to hamper the normal differentiation of keratinocytes; however, the underlying
mechanisms responsible for this phenomenon are yet to be clarified. Here, we aimed to study the effects of HPV16
E6 and E7 oncogenes on the expression of involucrin (IVL), an established marker of keratinocyte differentiation, in
human foreskin keratinocyte (HFK) cells.
Results: The differentiation of HFK cells by serum and high calcium significantly increased both the mRNA and the
protein levels of IVL. The E6 and E7 oncoproteins of HPV16 together caused strong down-regulation of IVL mRNA
and protein both in proliferating and in differentiating HFK cells. To study the effects of HPV oncogenes on the IVL
promoter, we made transient transfection assays and luciferase tests and found that HPV 16 E6 but not E7
repressed IVL promoter activity in proliferating HFK cells. The inhibitory effect of HPV 16 E6 on the human IVL
promoter could be localised to the proximal regulatory region (PRR) of the gene.
Conclusions: These results suggest that the down-regulation of IVL promoter activity by HPV 16 E6 significantly
contribute to the inhibition of endogenous IVL expression by the HPV 16 oncoproteins. In contrast, the down-
regulation of endogenous IVL expression by HPV16 E7 is probably not caused by a direct and specific effect of E7
on the IVL promoter.
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Background
Papillomaviruses are small DNA viruses, with a circular
double-stranded DNA genome of about 8 kbp length
[1]. Over 100 human papillomavirus (HPV) types have
been identified until now, of which about 40 is able to
infect the genital mucosa [2]. Low-risk HPV types (HPV
6, 11, 42) are mainly found in benign genital lesions
(condyloma acuminatum) or low grade cervical dyspla-
sias, while high-risk or oncogenic genital types (HPV 16,
18, and others) are causally linked to the development
of cervical cancer [3].
The E6 and E7 oncoproteins of high-risk HPVs are
responsible for the transforming activity of the virus [4].
High-risk HPV E6 induces the degradation of the p53
tumour suppressor protein through the ubiquitin-pro-
teosome pathway [5]. In addition, HPV E6 is able to
bind several other cellular proteins, some of which can
mediate transforming activity independently from the
p53 pathway [5]. High-risk HPV E7 is able to bind to
the pRB (retinoblastoma) tumour suppressor protein,
resulting in the functional inactivation and degradation
of pRB [6]. By binding to pRB/E2F complex and, by
releasing free E2F transcription factors, HPV E7 induces
the progression of the cell cycle [6].
The life cycle of human papillomaviruses is closely
linked to keratinocyte differentiation. HPVs initially
infect proliferating basal cells of the squamous epithe-
lium, while virus production is associated with terminally
differentiated layers [7]. The cellular DNA replication
machinery is reactivated by the E7 oncogene in differen-
tiating keratinocytes to provide a cellular environment
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[7,8]. This activity of HPV 16 E7 was shown to delay the
induction of the keratinocyte differentiation markers
involucrin and keratin 10 [9].
During the multi-step process of keratinocyte differen-
tiation, the expression of genes involved in the process
(such as keratins, transglutaminase 1, involucrin, etc.) is
tightly regulated. The presence of HPV 16 E6 oncogene
was shown to hamper the normal differentiation of ker-
atinocytes induced by serum and calcium or by normal
stratification in organotypic cell culture [10-12]. How-
ever, the underlying mechanisms responsible for the
perturbed differentiation of keratinocytes by the HPV
oncogenes are only partially elucidated.
It is reasonable to assume that the E6 and/or E7 onco-
genes may have an effect on the transcription of key cel-
lular genes involved in the differentiation of squamous
epithelium. Indeed, HPV 16 E6 was shown to modulate
the expression of several differentiation-associated genes
in human foreskin keratinocytes [13]. Using a xenograft
model, Lehr and co-workers showed that infection of
human keratinocytes by certain HPVs (type 11 and 59)
causes altered expression of certain CCE (cornified cell
envelope) proteins, such as loricrin and small proline
rich proteins (SPRR), both on the mRNA and on the
protein level [14,15]. However, it is not known whether
the HPV oncoproteins have effects on the promoters of
differentiation-regulated genes or exert their effects
post-transcriptionally.
The aim of this study was to investigate the effects of
HPV 16 E6 and E7 oncogenes on the expression of the
involucrin (IVL) and transglutaminase 1 (TG1)g e n e s ,
which are established markers of differentiation of squa-
mous epithelium. IVL protein is a 68 kDa, rod-shaped
molecule containing several glutamine residues. It is
found in the cytoplasm and cross-linked to membrane
proteins by keratinocyte transglutaminases in differen-
tiating keratinocytes [16].
Here, we found that the HPV oncogenes down-regu-
lated both IVL mRNA and protein levels in human fore-
skin keratinocyte (HFK) cells. In order to study the
molecular mechanisms that are responsible for the gene
expression alterations by the HPV oncoproteins, experi-
ments were performed using HPV 16 E6 and/or E7
expression plasmids along with luciferase reporter con-
structs containing parts of the regulatory region of the
human IVL gene.
Results
Generation and characterization of human foreskin
keratinocyte (HFK) cells expressing HPV 16 oncogenes
To study the effects of HPV oncogenes on the expres-
sion of cellular genes, human foreskin keratinocyte
(HFK) cells were transduced by recombinant
retroviruses carrying either the control vector (LXSN)
or vectors encoding HPV16 E6 or E7 or both onco-
genes. The presence of HPV E6 and/or E7 mRNA in the
transduced cells was demonstrated by RT-PCR (Figure
1 A ) .T h e2P C Rb a n d ss h o w no nF i g u r e1 A( u p p e r
panel) represent the full length E6 mRNA and the E6*I
spliced variant, in accordance with previous results [17].
T h ep r e s e n c eo ff u n c t i o n a l l ya c t i v eH P Vo n c o p r o t e i n s
was confirmed by demonstrating their effect on the level
of the cellular p53 oncoprotein (Figure 1B). As expected,
transduction of HPV16 E6 resulted in a decreased level
of p53 protein (about 10% of that seen in control trans-
duced cells, as indicated by densitometry), while expres-
sion of HPV 16 E7 led to the stabilization and thus
higher level (1.6-fold increase) of p53 protein [5,6].
The effects of the HPV oncogenes on the endogenous
mRNA levels of different cellular genes were studied using
real-time RT-PCR assays. In these experiments, cell lines
were used within 5 to 6 passages after transduction, as we
wanted to see the acute effects of the HPV oncogenes on
the expression of the cellular genes. The transduced cells
maintained the proliferating, non-differentiating pheno-
type when left in serum-free medium, while differentiation
was induced by changing the culture medium to DMEM
(with serum and high calcium) for 24 h, in accordance
with the results of previous studies [9,11]. An established
function of the HPV 16 E6 oncogene is the transcriptional
trans-activation of the human TERT (telomerase reverse
transcriptase) promoter [18,19]. Accordingly, the presence
of E6 led to a considerable (about 300-fold) increase in the
level of TERT mRNA (p < 0.001), while E7 had a weaker
b u ts t i l ls i g n i f i c a n t( p < 0.05) effect (Figure 2A). As
expected, induction of differentiation had no significant
effect on the level of TERT mRNA in any of the trans-
duced cells.
Effects of HPV 16 oncogenes on the expression of
selected cellular genes involved in keratinocyte
differentiation
Real-time RT-PCR assays were used to examine the
effects of the HPV oncogenes on the expression of the
squamous differentiation marker transglutaminase 1
(TG1) and one of its major substrate involucrin (IVL)i n
HPV oncogene transduced cells. As expected, induction
of differentiation of HFK cells by serum and increased
calcium resulted in highly increased levels of both IVL
and TG1 mRNA (p < 0.005) (Figure 2B and 2C). In pro-
liferating cells, both E6 and E7 had significant inhibiting
effect (p < 0.01) on IVL mRNA levels (Figure 2B). We
found a very strong down-regulation of IVL mRNA in
cells expressing both HPV oncoproteins (HFK-16E6E7)
compared to vector transduced (LXSN) cells (p < 0.001).
Both E6 and E7 caused significant (p < 0.001) down-reg-
ulation of IVL mRNA in differentiating HFK cells.
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Page 2 of 12Again, the strongest effect was seen in cells expressing
E6 and E7 together (p < 0.001). In proliferating cells,
H P V1 6E 6a n dE 7o n c o g e n e st o g e t h e rh a do n l y
moderate inhibiting effect on the endogenous mRNA
level of TG1 (p < 0.05), while in differentiating cells, the
HPV oncogenes had no significant effect on TG1
Figure 1 The expression of HPV oncogenes in transduced human foreskin keratinocyte (HFK) cells.( A) Cells were transduced by
recombinant retroviruses carrying either the control vector (LXSN) or vectors encoding HPV16 E6, E7, or E6/E7. The cells were either left in
serum-free medium (proliferating cells) or induced to differentiate in DMEM (with serum and high calcium). RT-PCR analysis was used to confirm
the expression of the appropriate HPV oncogenes in the different cell lines (GAPDH was used as an endogenous control). (B) The effect of
HPV16 E6 and E7 on the level of p53 protein. Protein extracts from transduced cells were subjected to Western blot assay for p53 or actin (the
latter as loading control). Parts of representative X-ray films are shown.
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Page 3 of 12Figure 2 The effect of HPV oncogenes on the mRNA levels of selected genes in HFK cells. Generation of cell lines and induction of
differentiation was performed as described in the legend to Figure 1. Relative Quantification (RQ) values were obtained by real-time RT-PCR
analysis to see the effects of HPV 16 oncogenes on the level of TERT (A), IVL (B), or TG1 (C) mRNA in HFK cells. The RQ value of proliferating
cells transduced by LXSN was set to 1, and other values are shown relative to this. Each reaction was performed in triplicate at least three times.
Representative graphs are shown, with error bars indicating standard deviation.
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Page 4 of 12mRNA expression (Figure 2C). These results suggest
that the effect of the HPV oncogenes on IVL expression
is either more direct or more specific than that on TG1
expression.
To see the effects of the HPV oncogenes on the level
of the IVL protein, we performed Western blot analysis
using monoclonal antibody to IVL (Figure 3). Induction
of differentiation by serum and high calcium resulted in
increased IVL protein levels, as compared to that seen
in proliferating cells. In proliferating cells, HPV 16 E6
or E7 alone had little effect on endogenous IVL protein,
while the two oncogenes together caused strong down-
Figure 3 The effect of HPV oncogenes on the level of IVL protein in HFK cells. Generation of cell lines and induction of differentiation was
performed as described in the legend to Figure 1. Ten μg of protein extracts prepared from the indicated cell lines were subjected to Western
blot analysis for IVL or actin protein (the latter as loading control). (A) Parts of representative X-ray films are shown. (B) The amount of IVL
protein was quantitatively analyzed by densitometry and standardized to actin protein level. The standardized density value of cycling cells
transduced by LXSN was set to 1, and other values are shown relative to this. Values show the means from four independent experiments with
standard errors shown as error bars.
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found in vector transduced (LXSN) cells (p < 0.001).
This down-regulating effect of E6/E7 on IVL protein
level was smaller but still significant in differentiating
cells (p = 0.032).
Effects of HPV 16 oncogenes on the transcriptional
activity of the human IVL promoter
Next, we aimed to determine whether the down-regulation
of IVL expression by the HPV oncoproteins was caused by
inhibiting the transcriptional activity of the IVL promoter.
To this end, low-passage HFK cells were transiently trans-
fected by either vector control or HPV 16 E6 and/or E7
expression vectors along with luciferase reporter con-
structs containing the regulatory region of the human IVL
gene. In pilot experiments, we used an internal control
vector (a Renilla luciferase reporter vector) to standardize
for transfection efficiency. However, we found that HPV
16 E6 expression had an effect on the activity of the inter-
nal control vector. Therefore, here we show luciferase
results obtained by standardization for protein concentra-
tion. The expression of functionally active HPV 16 E6 and
E7 proteins in the transfected HFK cells was confirmed by
co-transfection of reporter constructs containing either
binding sites for the p53 protein or the adenovirus E2
(AdE2) promoter carrying binding site for the E2F tran-
scription factor. As expected, the expression of HPV 16 E6
caused the down-regulation of the p53 reporter construct
in proliferating HFK cells (Figure 4A), while HPV 16 E7
increased the activity of the adenovirus E2 promoter (Fig-
ure 4B).
In proliferating HFK cells, HPV 16 E6 caused significant
down-regulation of a reporter construct (pGL3-IVL) con-
taining the full-length regulatory region of the human IVL
gene (p < 0.001). On the contrary, E7 alone had no signifi-
cant effect (p = 0.485) on the IVL reporter construct in
proliferating cells (Figure 4C). Induction of differentiation
by serum and high calcium resulted in highly (15-fold)
increased activity of the pGL3-IVL construct in the pre-
sence of the empty expression vector pcDNA. In differen-
tiating HFK cells, both HPV 16 E6 (p = 0.124) and E7 (p =
0.253) had a non-significant tendency to inhibit IVL pro-
moter activity, while HPV 16 E6 and E7 together caused
significant down-regulation of the IVL promoter (p =
0.014) (Figure 4C). Taken together, these results indicate
that the down-regulation of IVL promoter activity by HPV
16 E6 significantly contribute to the inhibition of endogen-
ous IVL expression by the HPV 16 oncoproteins.
Localisation of the effects of HPV 16 oncogenes on the
human IVL promoter
In order to localise the effects of HPV 16 oncogenes on
the human IVL promoter, a series of luciferase reporter
vectors was constructed carrying different fragments of
the promoter all extending to nt +41 relative to the
transcriptional start site (Figure 5A). First, we checked
in transient transfection experiments whether these con-
structs responded to differentiation stimuli in HFK cells.
As shown on Figure 5B, the activity of each reporter
construct was induced by differentiation of HFK cells.
Induction by differentiation was highest (15-fold) for the
longest construct (IVL-2418), while it was lower (about
4-fold) for the shorter IVL promoter constructs. Next,
we studied the effects of HPV 16 E6 and E7 on the tran-
scriptional activity of the IVL reporter constructs in
HFK cells. In proliferating HFK cells, HPV 16 E6 was
able to down-regulate transcription from each reporter
construct. When compared to vector control transfected
cells, E6 reduced the activity of the full-length reporter
construct IVL-2418 (p = 0.026) and also that of the
shortest reporter construct IVL-272 (p = 0.011) contain-
ing only the PRR (proximal regulatory region) of the
IVL promoter (Figure 5C). E6 caused significant down-
regulation of all the tested IVL reporter constructs also
in differentiating HFK cells (Figure 5D). These results
indicate that most of the down-regulating activity of
HPV 16 E6 on the human IVL promoter can be mapped
to the proximal regulatory region of the IVL gene (to
the promoter region -231 to +41 relative to the tran-
scriptional start site).
HPV 16 E7 had no significant effect on any IVL repor-
ter construct in proliferating cells (Figure 5C). In differ-
entiating cells, E7 had a moderate but significant
inhibiting effect (p =0 . 0 2 0 )o nt h ef u l l - l e n g t hI V L
reporter construct (IVL-2418), while it had no signifi-
cant effect on the shorter IVL reporter constructs.
Discussion
In this study, we found that the HPV 16 E6 and E7 onco-
proteins caused a synergistic down-regulation of endo-
genous IVL mRNA and protein levels in HFK cells,
which are natural host cells of the virus. Our finding is in
accordance with previous studies performing microarray
analysis of genes involved in cervical carcinogenesis. IVL
and/or other keratinocyte differentiation associated genes
(such as certain keratins and small prolin-rich proteins)
are down-regulated in cervical cancer specimens com-
pared to normal cervical samples [20,21]. Accordingly,
several studies using cultured human keratinocytes as in
vitro models for cervical carcinogenesis found that the
expression of HPV oncogenes causes a down-regulation
of expression of IVL and/or other genes involved in
epithelial differentiation [13,22,23]. However, microarray
analysis does not provide information on the mechanism
of changes in gene expression. Therefore, our approach
was to analyse in HFK cells gene expression alterations of
a few selected genes involved in keratinocyte differentia-
tion using reliable real-time RT-PCR assays and to
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Page 6 of 12Figure 4 The effect of HPV oncogenes on the transcriptional activity of different promoters in HFK cells.( A)H F Kc e l l sw e r ec o -
transfected with 0.5 μg of the p53 reporter construct p53-Luc, along with 0.25 μg of either control vector (pcDNA) or 0.25 μg of expression
constructs encoding HPV16 E6 or E7 or both expression vectors (0.125-0.125 μg) as indicated. (B) HFK cells were co-transfected with 0.5 μgo f
the adenovirus E2 reporter construct pAdE2Luc, along with 0.25 μg of either control vector (pcDNA) or 0.25 μg of expression constructs
encoding HPV16 E6 or E7 or both as indicated. (C) HFK cells were co-transfected with 0.5 μg of the IVL reporter construct pGL3-IVL, along with
0.25 μg of either control vector (pcDNA) or 0.25 μg of expression constructs encoding HPV16 E6 or E7 or both as indicated. After transfection,
HFK cells were either left in serum-free medium or induced to differentiate in DMEM (with serum and high calcium). The luciferase activities are
shown relative to the activity of cells co-transfected with reporter constructs and the empty expression vector (pcDNA). Data are from at least
three independent experiments with standard errors shown as error bars.
Gyöngyösi et al. Virology Journal 2012, 9:36
http://www.virologyj.com/content/9/1/36
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sion alterations using luciferase reporter assays. We also
found it important to study the effects of the HPV onco-
genes on the expression of differentiation-regulated
genes both in proliferating and in differentiating HFK
cells as we thought that differentiating cells rather than
proliferating cells reflect better the cellular environment
required for the productive life cycle of HPV.
As expected, induction of differentiation of keratino-
cytes highly increased the endogenous mRNA levels of
both IVL and TG1 in HFK cells (Figure 2). Interestingly,
the HPV 16 E6 and E7 oncogenes together had a very
strong down-regulating effect on IVL mRNA but only a
moderate effect on TG1 m R N A .T h i ss u g g e s t st h a tt h e
HPV oncogenes may have different effects on the expres-
sion of different genes involved in the differentiation of
Figure 5 Localisation of the effects of HPV 16 oncogenes on the human IVL promoter.( A) Schematic representation of reporter constructs
containing different parts of the human IVL promoter. The IVL promoter fragments were cloned in the reporter vector pGL3 in front of the
luciferase gene. Nucleotide positions are given relative to the transcription start site. Selected transcription factor recognition sites are indicated
(C/EBP, CCAAT enhancer binding protein). (B) The effect of differentiation on the transcriptional activity of constructs containing different
fragments of the IVL promoter in human foreskin keratinocytes. HFK cells were co-transfected with pGL3 luciferase reporter constructs containing
different fragments of the human IVL promoter (IVL-2418, IVL-1809, IVL-744, IVL-272) along with pcDNA control vector. Cells were left in serum-
free medium or induced to differentiate in DMEM with serum and high calcium. (C) and (D) The effect of HPV 16 E6 or E7 oncogenes on the
transcriptional activity of constructs containing different fragments of IVL promoter in proliferating (C) or in differentiating (D) HFK cells. HFK cells
were co-transfected with pGL3 luciferase reporter constructs along with either control vector (pcDNA) or expression constructs encoding HPV16
E6 or E7. The luciferase activities are shown relative to the activity of cells co-transfected with IVL-2418 reporter construct along with the control
vector. Data are from three independent experiments with standard errors shown as error bars.
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Page 8 of 12squamous epithelial cells. Western blot analysis showed
that the joint effect of HPV 16 E6 and E7 on transcrip-
tional down-regulation resulted in excessive decrease of
IVL protein levels as well, both in proliferating and in dif-
ferentiating cells (Figure 3). In a previous study, the
expression of HPV 6 or HPV 16 E7 was shown to result
in a decrease of IVL protein levels in HFK cells [24]. We
can conclude that the HPV 16 E6 and E7 oncogenes
together seem to down-regulate basal IVL expression and
also decrease the differentiation-induced expression of
the IVL gene in HFK cells.
The expression of genes involved in keratinocyte dif-
ferentiation (including IVL) are generally regulated on
the level of transcription [25]. Therefore, it seemed rea-
sonable to investigate the effects of HPV 16 oncopro-
teins on IVL promoter activity. This approach included
transfecting HFK cells by HPV 16 E6 and/or E7 expres-
sion vectors along with luciferase reporter constructs
containing the whole upstream-regulatory region (URR)
of the human IVL gene. In agreement with previous
results [26], differentiation of HFK cells led to a signifi-
cant increase in the transcriptional activity of the IVL
promoter. In proliferating HFK cells, HPV 16 E6, but
not E7 caused a significant down-regulation of IVL pro-
moter activity. The HPV 16 E6 and E7 oncoproteins
together caused a down-regulation of IVL promoter
activity in differentiating HFK cells (Figure 4). Taken
together, these results suggest that the down-regulation
of endogenous IVL mRNA and protein levels in HFK
cells by the HPV 16 E6 oncoprotein is caused by inhibi-
tion of IVL promoter activity. However, it can not be
ruled out that HPV 16 E6 down-regulates the expression
of IVL or other differentiation-associated genes also by
other mechanisms. For example, HPV 16 E6 was shown
to down-regulate the expression of Notch1, which was
suggested to have a role in the suppression of keratino-
cyte differentiation by E6 [27].
In order to localise the effect of the HPV oncogenes
within the IVL promoter, we made luciferase reporter
constructs containing different parts of the URR of the
human IVL gene. The URR of the human IVL gene con-
tains a distal regulatory region (DRR, -2473/-1953 from
transcription start site) and a proximal regulatory region
(PRR, -241/-7 from the transcription start site) [26].
From the 5 possible AP1 (activator protein 1) binding
sites in the URR, AP1-5 (in DRR) and AP1-1 (in PRR) are
essential for optimal promoter activity [28]. AP1 factors
(c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD) are
expressed at specific epidermal layers and the expression
pattern of these factors is thought to have a role in differ-
entiation-regulated gene expression in keratinocytes
[25,29,30]. Fra-1, junB and junD interact with AP1 sites
within the human IVL promoter and mediate phorbol
ester responsiveness [28]. In our experiments, the level of
inhibition by HPV 16 E6 was the highest for the con-
struct containing the whole URR of the IVL gene, but an
IVL reporter construct carrying only the PRR was still
significantly inhibited by the HPV 16 E6 protein, both in
proliferating and in differentiating HFK cells (Figure 5).
This suggests that the PRR of IVL gene contains binding
sites for transcription factors that are regulated by HPV
16 E6.
HPV 16 E7 had a significant inhibitory effect only on
the construct containing the full-length IVL promoter
(IVL 2418), and this effect was seen only in differentiat-
ing cells (Figure 5). This may suggest that the effect of E7
on the IVL promoter is less direct and/or less specific
than that of E6. We find it conceivable that the effects of
E7 seen on IVL expression (synergistic down-regulating
effect with E6) and on IVL promoter (slight down-regula-
tion only in differentiating cells) are caused not by a
direct and specific interaction with the IVL promoter, but
rather by recently described other mechanisms. For
instance, the DEK protein was found to be transcription-
ally up-regulated by HPV 16 E7, and this was shown to
be important in the induction of cell proliferation and
inhibition of the epithelial differentiation program
[31,32]. Furthermore, nucleophosmin (NPM) was
reported to be up-regulated by HPV 16 E7 at the post-
transcriptional level, and this up-regulation was sug-
gested to have a role in the inhibition of differentiation in
keratinocytes [33].
Both the DRR and the PRR of the human IVL gene
contains binding sites for AP1 transcription factors
(PRR). The promoters of differentiation-associated kerati-
nocyte genes usually contain binding sites for the AP1
factors, and these are thought to be important in the reg-
ulation of gene expression by differentiation stimuli
[25,29]. It is also interesting to note that the HPV 16 E7
protein was shown to bind to AP1 transcription factors,
including c-jun, junB, junD and c-fos [34]. Therefore, we
suppose that the AP1 motifs in the promoter of the
human IVL g e n em a yh a v ear o l ei nt h er e g u l a t i o no f
gene expression by HPV oncoproteins. In order to prove
this hypothesis, further research will be required using
promoter mutagenesis and chromatin immunoprecipita-
tion (ChIP) assays. It would be also interesting to study
the effects of the HPV oncogenes on the expression of
other genes (such as keratins, small prolin-rich proteins,
S100 calcium binding proteins) involved in keratinocyte
differentiation.
The decreased expression of IVL and other differentia-
tion-regulated genes by the HPV oncoproteins may have
an important role in the productive life cycle of the
virus. HPV replication takes place in differentiating
epithelial cells, which would exit the cell cycle in the
absence of viral infection. The E7 oncogene is able to
induce the progression of the cell cycle in differentiating
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tion [6,7]. On the other hand, the ability of the E6 onco-
gene to cause a delay in the induction of epithelial
differentiation may also have a role in providing a cellu-
lar environment that is favourable for HPV replication.
Our results indicate that one possible mechanism of the
inhibition of keratinocyte differentiation by E6 may be
the down-regulation of promoters of certain differentia-
tion-regulated genes.
Conclusions
In this study, the human papillomavirus 16 (HPV 16) E6
and E7 oncogenes were found to have strong synergistic
inhibitory effect on the expression of endogenous IVL
mRNA and protein, both in replicating and in differen-
tiating human foreskin keratinocyte (HFK) cells. In non-
differentiating HFK cells, HPV 16 E6 but not E7 down-
regulated the activity of the human IVL promoter, and
this effect could be localized to the proximal regulatory
region (PRR) of the promoter. Our results indicate that
the down-regulation of IVL promoter activity by HPV
16 E6 significantly contribute to the inhibition of endo-
genous IVL expression by the HPV 16 oncoproteins. In
contrast, the down-regulation of endogenous IVL
expression by HPV16 E7 is probably not caused by a
direct and specific effect of E7 on the IVL promoter.
Methods
Cell culture and retroviral transduction
Primary human foreskin keratinocytes (HFK) were
obtained from Invitrogen. HFK cells were cultured in
Defined Keratinocyte-Serum Free Medium containing <
0.1 mM calcium (DK-SFM, Invitrogen). PA317-LXSN,
-16E6, -16E7, and -16E6E7 cells are recombinant retro-
virus producing cell lines from the ATCC (American
Type Culture Collection). These cell lines were main-
tained in Dulbecco’sm o d i f i e dE a g l e ’s medium (DMEM)
supplemented with 10% foetal calf serum, 2 mM L-glu-
tamine and antibiotics (100 U/ml penicillin and 100 μg/
ml streptomycin). Primary keratinocytes were infected
with culture supernatants from PA317 cell lines produ-
cing the control LXSN virus or LXSN-based retroviral
vectors expressing HPV16 E6, HPV16 E7 or HPV16 E6/
E7 genes. These cells were selected in media containing
G418 (100 μg/ml). Infected HFKs were either left
untreated or induced to differentiate by culturing in
DMEM (containing 1.8 mM calcium and 10% foetal calf
serum) for 24 h.
Plasmid constructs
The luciferase reporter vector pGL3-IVL, containing a
3.7 kb fragment of the human IVL gene regulatory
region was described previously [35]. The other frag-
ments of IVL promoter were created by PCR using
pGL3-IVL as template and cloned into pGL3-Basic (Pro-
mega) between the XhoIa n dHindIII restriction sites
resulting pGL3-IVL-2418, pGL3-IVL-1809, pGL3-IVL-
744 and pGL3-IVL-272 (Table 1). Amplifications were
performed with GeneAmp High Fidelity System
(Applied Biosystems) according to the manufacturer’s
protocol. The resulting clones were verified by sequen-
cing. The p53-Luc reporter plasmid containing several
copies of the p53 binding site was purchased from Agi-
lent Technologies. The pAdE2Luc reporter construct
containing the adenovirus E2 promoter was kindly pro-
vided by Dr. Ann Roman [36]. The pcDNA-16E6 and
pcDNA-16E7 expression vectors were described pre-
viously [37].
Transient transfection
Primary human keratinocytes (within 3-6 passages) were
plated on 6-well plates at approximately 80% confluence.
The cells were co-transfected by 0.5 μgo fIVL promo-
ter-luciferase constructs (pGL3-IVL, pGL3-IVL-2418,
pGL3-IVL-1809, pGL3-IVL-744 or pGL3-IVL-272)
along with 0.25 μg of expression vectors (pcDNA)
encoding HPV 16 E6 and/or E7 genes using Effectene
(Qiagen). The total amount of expression vectors was
kept constant (0.25 μg) in all transfection experiments.
Transfection mix was added to cells in Opti-MEM (Invi-
trogen) and incubated for 5 h at 37°C, after which the
medium was changed to DK-SFM. Twenty-four hours
after transfection, HFKs were either left untreated or
induced to differentiate in DMEM (containing 1.8 mM
calcium and 10% foetal calf serum for 24 h). The cells
were washed with PBS (phosphate buffered saline) 48 h
after transfection and lysed in Reporter Lysis Buffer
(Promega). A Berthold luminometer and Luciferase
assay system (from Promega) was used to measure luci-
ferase activity. Bradford protein assay was performed to
standardize for the protein concentration of the cell
Table 1 Sequences of PCR primers used to construct
luciferase reporter vectors containing different fragments
of the human IVL promoter
Plasmid
construct
Primer sequence (5’ to 3’) Restriction
site
pGL3-IVL-2418 GCGCCTCGAGCAGTGAAAGAACCTCTCCCA XhoI
GCGCAAGCTTCCATCCGACACTTACCAGAC HindIII
pGL3-IVL-1809 GCGCCTCGAGATGATCCAGGAACATGACAA XhoI
GCGCAAGCTTCCATCCGACACTTACCAGAC HindIII
pGL3-IVL-744 GCGCCTCGAGTTCTTATGAGCATGGCATTC XhoI
GCGCAAGCTTCCATCCGACACTTACCAGAC HindIII
pGL3-IVL-272 GCGCCTCGAGAGTTGAGCTACCAGAATCCT XhoI
GCGCAAGCTTCCATCCGACACTTACCAGAC HindIII
PCR products amplified using the indicated primers were digested by XhoI
and HindIII and cloned into the luciferase reporter vector pGL3
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independently at least three times.
RT-PCR
Total RNA was isolated from proliferating or differen-
tiating transduced cells by using TRI reagent (Sigma).
The High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) was used to prepare cDNA. The
PCR reaction was performed with GoTaq DNA poly-
merase (Promega) according to the manufacturer’sp r o -
tocol. The primer pairs used for amplifying HPV16 E6,
E7 and GAPDH (glyceraldehyde 3-phosphate dehydro-
genase) were previously described [38].
Real-time RT-PCR
After total RNA isolation, cDNA was synthesised as
described above. The real-time PCR was performed on
the 7500 Real Time PCR System (Applied Biosystems)
using TaqMan Gene Expression Master Mix and Assays
according to the manufacturer’sr e c o m m e n d a t i o n s
(Applied Biosystems). The PCR amplification was car-
ried out in a total volume of 20 μl. The TaqMan Gene
Expression Assays used were for involucrin (IVL;
Hs00846307_s1), transglutaminase 1 (TG1;
Hs00165929_m1), cyclin-dependent kinase inhibitor 2A
(CDKN2A, p16-INK4A; Hs00923894_m1), telomerase
reverse transcriptase (TERT; Hs00162669_m1) and gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH;
0711024) as endogenous control (Applied Biosystems).
Each PCR reaction was performed in triplicate at least
three times.
Western blot
Protein extract from proliferating or differentiating
transduced HFK cells were prepared in RIPA lysis buffer
(150 mM NaCl, 1% NP-40, 50 mM Tris-HCl pH 8.0,
0.5% Na-dezoxycholate, 0.1% SDS, 0.01% Na-azide, 1
mM EDTA, pH 7.4) supplemented with Complete
EDTA-free Protease Inhibitor Cocktail (Roche). Cells
were scraped, incubated on ice, and after centrifugation
the supernatants were collected. The protein concentra-
tion of the lysates was measured by Bradford protein
assay. Ten μg of protein extracts was electrophoresed
through 10% polyacrilamide gels (SDS-PAGE) and elec-
troblotted into nitrocellulose membrane. Membranes
were blocked in Tris buffered saline-Tween (TBST: 10
mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.9) con-
taining 5% non-fat dry milk. The blots were incubated
with primary antibodies overnight at 4°C. The following
primary antibodies were diluted 1:2000 in 5% non-fat
dry milk in TBST: mouse monoclonal anti-involucrin
(sc-56555), mouse monoclonal anti-p53 (sc-126) from
Santa Cruz Biotechnology and rabbit polyclonal anti-
actin (A2066) from Sigma. After washing in TBST, the
membrane was incubated for 1 h with goat anti-mouse
(sc-2005) or goat anti-rabbit (sc-2004) secondary antibo-
dies conjugated with horseradish peroxidase (Santa Cruz
Biotechnology) diluted 1:5000 in 5% non-fat dry milk in
TBST. Following washes in TBST, antibody complexes
were visualized using the SuperSignal West Pico Chemi-
luminescent Substrate (Pierce) and exposed to X-ray
films. The amounts of proteins were quantitatively
determined by densitometry using Gel Doc 2000 gel
documentation system (Bio-Rad) and the Quantity One
(version 4.0.3) software. Protein levels of IVL and p53
were normalized to actin levels.
Statistical analysis
For the analysis of real-time RT-PCR results, the com-
parative Ct method was used to obtain the Relative
Quantification (RQ) values with standard deviation and
confidence intervals (7500 System SDS Software, version
1.4). To analyse the results of luciferase tests, mean and
SEM (standard error of mean) of standardized luciferase
values (from at least 3 independent experiments) were
calculated, and the significance of differences between 2
mean values was evaluated using the 2-sample t-test.
Significance was accepted at p < 0.05.
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